Daiichi Sankyo
Clinical trials sponsored by Daiichi Sankyo, explained in plain language.
A global pharmaceutical company developing innovative medicines, notably in oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Triple-Drug cocktail aims to reverse early heart disease
Disease control Not yet recruitingThis Phase 3 trial will test whether a combination of three cholesterol-lowering drugs—bempedoic acid, ezetimibe, and a high-intensity statin—can reduce and stabilize plaque buildup in the coronary arteries. The study enrolls 103 adults with coronary atherosclerosis who have neve…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an experimental drug called DS-3939a in adults with advanced solid tumors, including a type of lung cancer. The study has two parts: the first checks safety and the best dose, and the second looks at whether the drug, alone or with other cancer treatments, c…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug sequence aims to outsmart advanced breast cancer
Disease control Not yet recruitingThis trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Double-Barreled drug attack targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC